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INTRODUCTION 
Patients with chronic renal failure often have signs & symptoms 
suggestive of thyroid dysfunction. These findings include dry skin, sallow 
complexion, low temperature, cold intolerance, decreased basal metabolic 
rate, lethargy, fatigue, edema & hyporeflexia. Various studies of thyroid 
functions in uremic patients have been carried out which have shown 
conflicting results. Hyperthyroidism, hypothyroidism & euthyroid state have 
all been reported by various workers. 
Serum triiodothyronine (T3) levels were consistently found to be low 
without any regard to treatment of CRF. Serum total & free thyroxine (T4) 
concentrations have been reported as low, normal or high. Serum thyroid 
stimulating hormone (TSH) levels were found to be normal in most patients 
of CRF even in those whose CRF is complicated by low T3 concentration. 
A reduction in total T3, but not in free T3 concentrations 
was associated with an increased all-cause and cardiovascular mortality in 
euthyroid CKD patients45. Total and free T3 behave as survival markers in 
patients with CKD both in HD and in PD. 
Prevalence of hypothyroidism in end stage renal disease (ESRD) have 
been estimated between 0 and 9%. There is also increased prevalence of 
goiter in patients with ESRD. Though there are multiple factors which 
predicts the overall mortality and severity of renal disease, one among the 
important factor is thyroid dysfunction. So it is prudent for the internist and 
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treating physician to be aware of thyroid dysfunction so that early 
intervention can be instituted to improve the outcome. In view of variability 
of thyroid function test in patients with CRF in previous studies, a cross-
sectional study on thyroid function in CRF patient in Department of 
Medicine, TIRUNELVELI Medical College Hospital, has been undertaken. 
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AIM OF THE STUDY 
        
1. To study the prevalence of thyroid dysfunction in patients with 
chronic renal failure. 
 
2. To study the correlation between thyroid dysfunction and severity 
of renal failure. 
                  
3. To differentiate primary thyroid diseases from thyroid 
dysfunction due to chronic renal failure. 
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REVIEW OF LITERATURE 
 
Chronic kidney disease (CKD)1 encompasses a spectrum of different 
pathophysiologic processes associated with abnormal kidney function, and a 
progressive decline in glomerular filtration rate (GFR). 
DEFINITION CRITERIA: 
Chronic Kidney Disease is defined according to the presence or 
absence of markers of kidney damage and the level of kidney function 
(GFR), irrespective of kidney disease (the specific diagnosis). 
1. Kidney damage for ≥3months,as defined by structural or functional 
abnormalities of the kidney, with or without decreased GFR, manifest by 
either, 
a) Pathological abnormalities or 
b) Markers of kidney damage, including abnormalities in the 
composition of the blood or urine or abnormalities in imaging tests. 
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CLASSIFICATION: 
A widely accepted classification, based on recent guidelines of the 
National Kidney Foundation [Kidney Dialysis Outcomes Quality Initiative 
(KDOQI)]2, in which stages of CKD are defined according to the estimated 
GFR. 
Stage GFR ml/min/1.73m2 
0 >90a 
1 >90b 
2 60-89 
3 30-59 
4 15-29 
5 <15 
 
a. with risk factors for CKD 
b. with demonstrated kidney damage (persistent protienuria, abnormal 
urine sediment, abnormal blood and urine chemistry, abnormal 
imaging studies)  
PATHOPHYSIOLOGY: 
The pathophysiology of CKD involves two broad sets of mechanisms of 
damage:  
1. Initiating mechanisms specific to the underlying etiology (e.g: 
immune complexes and mediators of inflammation in certain types of 
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glomerulonephritis or toxin exposure in certain diseases of the renal 
tubules and interstitium), 
2. Set of progressive mechanisms, involving hyperfiltration and 
hypertrophy of the remaining viable nephrons, that are a common 
consequence following long-term reduction of renal mass, irrespective 
of underlying etiology. The responses to reduction in nephron number 
are mediated by vasoactive hormones, cytokines, and growth factors. 
Eventually, these short-term adaptations of hypertrophy and 
hyperfiltration become maladaptive as the increased pressure and flow 
predisposes to sclerosis and dropout of the remaining nephrons.  
UREMIA: 
Hundreds of toxins that accumulate in renal failure have been 
implicated in the uremic syndrome. These include water-soluble, 
hydrophobic, protein-bound, charged and uncharged compounds. Additional 
categories of nitrogenous excretory products include guanido compounds, 
urates and hippurates, products of nucleic acid metabolism, polyamines, 
myoinositol, phenols, benzoates, and indoles. Compounds with a molecular 
mass between 500 and 1500 Da, the so-called middle molecules, are also 
retained and contribute to morbidity and mortality. The pathophysiology of 
the uremic syndrome can be divided into manifestations in three spheres of 
dysfunction: (1) those consequent to the accumulation of toxins normally 
undergoing renal excretion, including products of protein metabolism                 
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(2) those consequent to the loss of other renal functions, such as fluid and 
electrolyte homeostasis and hormone regulation and (3) progressive systemic 
inflammation and its vascular and nutritional consequences. 
MANIFESTATIONS OF CHRONIC KIDNEY DISEASE 
Stages 1 and 2 CKD are usually not associated with any symptoms 
arising from the decrement in GFR. However, there may be symptoms from 
the underlying renal disease itself, such as edema in patients with nephrotic 
syndrome or signs of hypertension secondary to the renal parenchymal 
disease in patients with polycystic kidney disease, some forms of 
glomerulonephritis and many other parenchymal and vascular renal diseases, 
even with well-preserved GFR. If the decline in GFR progresses to stages 3 
and 4, clinical and laboratory complications of CKD become more 
prominent. Virtually all organ systems are affected, but the most evident 
complications include anemia and associated easy fatiguability, decreasing 
appetite with progressive malnutrition, abnormalities in calcium, phosphorus 
and mineral-regulating hormones, such as 1,25(OH)2D3 (calcitriol) and 
parathyroid hormone (PTH) and abnormalities in sodium, potassium, water 
and acid-base homeostasis. If the patient progresses to stage 5 CKD, toxins 
accumulate such that patients usually experience a marked disturbance in 
their activities of daily living, well-being, nutritional status and water and 
electrolyte homeostasis, eventuating in the uremic syndrome 
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PHYSIOLOGY OF THYROID HORMONES: 
The thyroid gland produces two related hormones, thyroxine (T4) and 
triiodothyronine (T3). Acting through nuclear receptors, these hormones play 
a critical role in cell differentiation during development and help to maintain 
thermogenic and metabolic homeostasis in the adult. Autoimmune disorders 
of the thyroid gland can either stimulate the overproduction of thyroid 
hormones (thyrotoxicosis) or cause glandular destruction and hormone 
deficiency (hypothyroidism). 
Iodide uptake is a critical first step in thyroid hormone synthesis. 
Ingested iodine is bound to serum proteins, particularly albumin. Unbound 
iodine is excreted in the urine. The thyroid gland extracts iodine from the 
circulation in a highly efficient manner. 
ORGANIFICATION, COUPLING, STORAGE AND RELEASE 
After iodide enters the thyroid, it is trapped and transported to the 
apical membrane of thyroid follicular cells, where it is oxidized in an 
organification reaction that involves TPO and hydrogen peroxide. The 
iodotyrosines in Tg are then coupled via an ether linkage in a reaction that is 
also catalyzed by TPO. Either T4 or T3 can be produced by this reaction, 
depending on the number of iodine atoms present in the iodotyrosines. After 
coupling, Tg is taken back into the thyroid cell, where it is processed in 
lysosomes to release T4 and T3. Uncoupled mono- and diiodotyrosines are 
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deiodinated by the enzyme dehalogenase, thereby recycling any iodide that 
is not converted into thyroid hormones. 
REGULATION OF THYROID AXIS 
TSH, secreted by the thyrotrope cells of the anterior pituitary, plays a 
pivotal role in control of the thyroid axis and serves as the most useful 
physiologic marker of thyroid hormone action. 
Hypothalamic TRH stimulates pituitary production of TSH, which in 
turn, stimulates thyroid hormone synthesis and secretion. Thyroid hormones 
feed back to inhibit TRH and TSH production. The "set-point" in this axis is 
established by TSH. TRH is the major positive regulator of TSH synthesis 
and secretion. Peak TSH secretion occurs ~15 min after administration of 
exogenous TRH. Dopamine, glucocorticoids and somatostatin suppress TSH 
but are not of major physiologic importance except when these agents are 
administered in pharmacologic doses. 
TSH is released in a pulsatile manner and exhibits a diurnal rhythm, 
its highest levels occur at night. TSH has a relatively long plasma half-life 
(50 min). 
FACTORS INFLUENCE THYROID HORMONE SYNTHESIS AND 
RELEASE: 
Although TSH is the dominant hormonal regulator of thyroid gland 
growth and function, a variety of growth factors, most produced locally in 
the thyroid gland, also influence thyroid hormone synthesis.  
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These include insulin-like growth factor I (IGF-I), epidermal growth 
factor, transforming growth factor (TGF), endothelins, and various 
cytokines. Excess iodide transiently inhibits thyroid iodide organification, a 
phenomenon known as the Wolff-Chaikoff effect. In individuals with a 
normal thyroid, the gland escapes from this inhibitory effect and iodide 
organification resumes. The suppressive action of high iodide may persist, in 
patients with underlying autoimmune thyroid disease. 
CHARACTERISTICS OF CIRCULATING T4 AND T3 
Hormone Property T4 T3 
Serum concentrations     
Total hormone 8ug/dL 0.14 ug/dL 
Fraction of total hormone in the free form 0.02% 0.3% 
Free (unbound) hormone 21 x 10-12 M  6 x 10-12 M  
Serum half-life 7 d 0.75 d 
Fraction directly from the thyroid 100% 20% 
Production rate, including peripheral 
conversion 
90 ug/d 32 ug/d 
Intracellular hormone fraction 20% 70% 
Relative metabolic potency 0.3 1 
Receptor binding 10-10 M  
 
10-11 M 
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ABNORMALITIES OF THYROID HORMONE BINDING 
PROTEINS: 
Mutations in TBG, TTR and albumin may increase the binding 
affinity for T4 and/or T3 and cause disorders known as euthyroid 
hyperthyroxinemia or familial dysalbuminemic hyperthyroxinemia (FDH). 
These disorders result in increased total T4 and/or T3, but unbound hormone 
levels are normal. 
Certain medications, such as salicylates and salsalate, can displace 
thyroid hormones from circulating binding proteins. Although these drugs 
transiently perturb the thyroid axis by increasing free thyroid hormone 
levels, TSH is suppressed until a new steady state is reached, thereby 
restoring euthyroidism. Circulating factors associated with acute illness may 
also displace thyroid hormone from binding proteins. 
DEIODINASES: 
T4 may be thought of as a precursor for the more potent T3. T4 is 
converted to T3 by the deiodinase enzymes. Type I deiodinase, which is 
located primarily in thyroid, liver and kidney, has a relatively low affinity for 
T4. Type II deiodinase has a higher affinity for T4 and is found primarily in 
the pituitary gland, brain, brown fat, and thyroid gland. Type II deiodinase is 
also regulated by thyroid hormone. Hypothyroidism induces the enzyme, 
resulting in enhanced T4 to T3 conversion in tissues such as brain and 
pituitary. T4 to T3 conversion is impaired by fasting, systemic illness or   
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acute trauma, oral contrast agents and a variety of medications 
(propylthiouracil, propranolol, amiodarone, glucocorticoids). Type III 
deiodinase inactivates T4 and T3 and is the most important source of reverse 
T3 (rT3). 
HYPOTHYROIDISM: 
Hypothyroidism is a clinical syndrome caused by decreased level of 
thyroid hormones. It can be primary in which there is intrinsic disorder of 
thyroid gland or it may be secondary in which there is pituitary or 
hypothalamic defect. 
Florid hypothyroidism can be diagnosed clinically. The symptoms of 
hypothyroidism in descending order of frequency are: 
• Tiredness, weakness 
• Dry Skin 
• Feeling Cold 
• Hair Loss 
• Difficulty in concentrating and poor memory 
• Constipation 
• Weight gain with poor appetite 
• Dyspnea 
• Hoarse voice 
• Menorrhagia (Later amenorrhea) 
• Paraesthesia 
• Impaired hearing 
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The signs of hypothyroidism in descending order of frequency are as 
follows: 
• Dry coarse skin 
• Cool peripheral extremities 
• Puffy face, hands and feet (myxedema) 
• Diffuse alopecia 
• Bradycardia 
• Peripheral edema 
• Delayed tendon reflex relaxation 
• Carpal tunnel syndrome 
• Serous cavity effusions 
In biochemical studies, TSH is the single most important parameter 
for screening hypothyroidism.  A normal TSH level rules out primary 
hypothyroidism, but not secondary. To diagnose primary hypothyroidism, 
TSH level should be above 20 μIU/ml or at least above 10 μIU/ml if clinical 
features strongly suggest. 
In the presence of elevated TSH, low T4 especially free T4 is 
necessary to confirm hypothyroidism. Circulating free T3 is usually reduced. 
But it may be normal in 25% of hypothyroid patients. So, T3 measurements 
are not reliable indicators of hypothyroidism. 
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HYPERTHYROIDISM: 
Hyperthyroidism is a clinical syndrome which results from exposure 
of the body tissues to excess circulating levels of free thyroid hormones. 
The symptoms of hyperthyroidism in descending order of frequency 
are as follows: 
• Hyper activity, irritability, dysphonia 
• Heat intolerance and sweating 
• Palpitations 
• Fatigue and weakness 
• Weight Loss with increased appetite 
• Diarrhoea 
• Polyuria 
• Oligomenorrhea, loss of libido 
The signs of hyperthyroidism in descending order of frequency are as 
follows: 
• Tachycardia; atrial fibrillation in elderly 
• Tremor 
• Goiter 
• Warm, moist skin 
• Muscle weakness, proximal myopathy 
• Lid retraction or lag 
• Gynaecomastia 
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Laboratory investigation shows TSH below normal level. Free and 
total thyroid hormone levels are increased. 
In 2 to 5% of patients, only T3 is increased, a condition called T3 
thyrotoxicosis. Occasionally, total and free T4 will be increased with normal 
T3 level. This condition is called T4 thyrotoxicosis. 
SICK EUTHYROID SYNDROME: 
Any acute, severe illness can cause abnormalities of circulating TSH 
or thyroid hormone levels in the absence of underlying thyroid disease, 
making these measurements potentially misleading. The major cause of these 
hormonal changes is the release of cytokines such as IL-6. Unless a thyroid 
disorder is strongly suspected, the routine testing of thyroid function should 
be avoided in acutely ill patients. 
The most common hormone pattern in sick euthyroid syndrome 
(SES) is a decrease in total and unbound T3 levels (low T3 syndrome) with 
normal levels of T4 and TSH. The magnitude of the fall in T3 correlates with 
the severity of the illness. T4 conversion to T3 via peripheral deiodination is 
impaired, leading to increased reverse T3 (rT3). Despite this effect, 
decreased clearance rather than increased production is the major basis for 
increased rT3. 
Very sick patients may exhibit a dramatic fall in total T4 and T3 levels 
(low T4 syndrome). This state has a poor prognosis. A key factor in the fall 
in T4 levels is altered binding to TBG. T4 assays usually demonstrate a 
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normal unbound T4 level in such patients, depending on the assay method 
used. Fluctuation in TSH levels also creates challenges in the interpretation 
of thyroid function in sick patients, levels may range from <0.1 to >20 
mU/L. The exact mechanisms underlying the subnormal TSH seen in 10% of 
sick patients and the increased TSH seen in 5% remain unclear but may be 
mediated by cytokines including IL-12 and IL-18. 
Any severe illness can induce changes in thyroid hormone levels, but 
certain disorders exhibit a distinctive pattern of abnormalities. Acute liver 
disease is associated with an initial rise in total (but not unbound) T3 and T4 
levels, due to TBG release. The levels become subnormal with progression 
to liver failure. A transient increase in total and unbound T4 levels, usually 
with a normal T3 level, is seen in 5–30% of acutely ill psychiatric patients. 
TSH values may be transiently low, normal or high in these patients. In the 
early stage of HIV infection, T3 and T4 levels rise, even if there is weight 
loss. T3 levels fall with progression to AIDS (Acquired immune Deficiency 
Syndrome), but TSH usually remains normal. Renal disease is often 
accompanied by low T3 concentrations, but with normal rather than 
increased rT3 levels, due to an unknown factor that increases uptake of rT3 
into the liver. 
Treatment of SES with thyroid hormone (T4 and/or T3) is 
controversial, but most authorities recommend monitoring the patient's 
thyroid function tests during recovery without administering thyroid 
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hormone, unless there is historic or clinical evidence suggestive of 
hypothyroidism. 
RELATION BETWEEN THYROID HORMONES AND KIDNEY: 
Thyroid hormones (TH) are necessary for growth and development of 
the kidney and for the maintenance of water and electrolyte homeostasis. On 
the other hand, kidney is involved in the metabolism and elimination of 
Thyroid Hormone. From a clinical practice viewpoint, it should be 
mentioned that both hypothyroidism and hyperthyroidism are accompanied 
by remarkable alterations in the metabolism of water and electrolyte, as 
well as in cardiovascular function. All these effects generate changes in water 
and electrolyte kidney management 11. Moreover, the decline of kidney 
function is accompanied by changes in the synthesis, secretion, metabolism 
and elimination of Thyroid Hormone. Thyroid dysfunction acquires special 
characteristics in those patients with advanced kidney disease. 
EFFECT OF THYROID HORMONES ON RENAL PHYSIOLOGY: 
Thyroid Hormone plays an important role in growth, development and 
physiology of the kidney12. It is known that hypothyroidism reduces and 
hyperthyroidism increases the kidney-to-body weight ratio by a not fully 
understood mechanism 13. 
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Thyroid Hormone have a hold upon tubular transport of sodium, via 
their actions on the sodium–potassium ATP pump (Na+/K+ ATPase) and 
on the potassium permeability in the membrane of proximal tubules 14, 15, 16. 
As it occurs with Na+, the reduction of TH activity at kidney level is 
accompanied by a decrease in the absorption of calcium at tubular level 
without affecting magnesium18. Thyroid Hormone stimulates renin release 
by the juxtaglomerular cells through a mechanism independent of the 
ouabain-sensitive sodium pump and protein synthesis19 and influence kidney 
angiotensinase activity 20.  
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EFFECTS OF THRYOID DYSFUNCTION ON THE KIDNEY: 
Thyroid dysfunction causes significant changes in kidney function. 
Both hypothyroidism and hyperthyroidism affect renal blood flow, GFR, 
tubular function, electrolytes homeostasis, electrolyte pump functions and 
kidney structure21. 
Hypothyroidism Thyrotoxicosis 
Increased serum creatinine Decreased serum creatinine 
Decreased glomerular filtration Increased glomerular filtration 
Decreased renal plasma flow Increased renal plasma flow 
Decreased sodium reabsorption Increased tubular reabsorption 
Decreased renal ability to dilute urine Resistance to rhEPO action? 
Hyponatremia  
 
KIDNEY DISEASE ASSOCIATED WITH THYROID 
DYSFUNCTION: 
Different types of kidney diseases can be associated with various 
disorders of thyroid function 22. 
Glomerular disease: 
Thyroid disease may be linked to different forms of 
glomerulonephritis 23. Both hypothyroidism  and hyperthyroidism can 
coincide with different forms of glomerular disease. The more frequent form 
is membranous glomerulopathy associated with nephrotic syndrome (NS) 24. 
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Thyroid dysfunction has been reported to be associated with IgA 
glomerulonephritis25, mesangiocapillary or membranoproliferative 
glomerulonephritis and minimal change glomerulonephritis . 
Several mechanisms have been involved in these 
associations. Proteinuria may promote the development of primary 
hypothyroidism and the immune activation of the thyroid or kidney 
disorders could induce the formation of immune complexes 26. The presence 
of immune complexes is common in patients with thyroid disease.                
33–55% patients with an autoimmune process have correlation with the 
presence of thyroid peroxidase antibodies, but not with the titre of these 
antibodies27. Several data support the autoimmune pathogenesis for the 
association: i) the association of kidney and thyroid diseases of autoimmune 
origin, ii) its association with other autoimmune diseases such as type 1 
diabetes and iii) the presence of deposits of immunoglobulins 
and thyroglobulin in the glomeruli of some patients28 . Although autoimmune 
thyroid disease has occasionally been reported in patients with 
glomerulonephritis, no causal relationship between the two disorders has 
been proved so far. Glomerular disease in general is associated and 
occasionally caused by autoimmune disease (e.g. lupus nephritis, 
antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis) that can 
be associated to autoimmune thyroid disease. 
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Tubular disease 
Although less frequent than glomerular disease, tubular or 
tubulointerstitial damage has also been reported to be associated with thyroid 
dysfunction 29. Isolated cases of hyperthyroidism have been reported in 
association with tubulointerstitial nephritis and uveitis, a self-limited 
syndrome of unknown etiology that responds to glucocorticoids30. In 
these cases, the etiology of hyperthyroidism was not Grave’s disease, but 
rather a destructive thyroiditis with the absence of thyroid autoimmunity, low 
uptake in thyroid scintigraphy, and adequate response to steroid therapy. 
Tubulointerstitial nephritis and hyperthyroidism has been reported to be 
associated in patients under treatment with rifampicin 31. 
Nephrotic syndrome 
Nephrotic Syndrome is associated with changes in serum Thyroid 
Hormone levels32. Urinary losses of binding proteins such as thyroxine 
binding globulin (TBG), transthyretin or pre-albumin, albumin and Thyroid 
Hormone bound to them, result in a reduction in serum total thyroxine (T4) 
and sometimes, in total T3 levels. These hormonal changes are related both 
to the degree of proteinuria and to serum albumin levels 33. However, 
patients often remain euthyroid, because free T4 and T3 levels are usually 
normal. This suggests that thyroid is able to compensate for hormonal 
urinary losses keeping the patient euthyroid. However, in patients with 
low thyroid reserve overt hypothyroidism can develop. Similarly, Nephrotic 
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Syndrome may increase the exogenous levothyroxine needs in patients with 
hypothyroidism. 
CHRONIC KIDNEY DISEASE: 
CKD affects both hypothalamus–pituitary–thyroid axis and TH peripheral 
metabolism. Uremia influences the function and size of the thyroid. Uremic 
patients have an increased thyroid volume compared with subjects with 
normal renal function and a higher prevalence of goiter, mainly in 
women36. Also, thyroid nodules and thyroid carcinoma are more common in 
uremic patients than in the general population. 
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Serum TSH concentrations are usually normal or elevated in CKD, but 
its response to its releasing hormone (TRH) is generally low. These findings 
suggest the presence of intrathyroidal and pituitary disturbances associated 
with uremia 37. Also, both TSH circadian rhythm and TSH glycosylation are 
altered in CKD. The latter may compromise TSH bioactivity. 
Free and total T3 and T4 concentrations are usually normal or low in 
patients with CKD. The reduction in T3 levels (low T3 syndrome) is the 
most frequently observed thyroid alteration in these patients. The reduction 
in T3 concentrations has been linked to a decrease in the peripheral synthesis 
of T3 from T4. Chronic metabolic acidosis associated with the CKD may 
contribute in this effect 38. Although free and total T4 concentrations may be 
normal or slightly reduced, sometimes free T4 may be high due to the effect 
of heparin used in anticoagulation during hemodialysis (HD), which inhibits 
T4 binding to its binding proteins. 
In CKD patients, the sick euthyroid state is characterized by the 
absence of total rT3 rising, a typical feature in other patients with non-
thyroidal disease39. Despite the fact that the total rT3 clearance in CKD 
patients is diminished, there is a redistribution of rT3 from the vascular to 
the extra vascular space and an increase in rT3 cellular uptake. However, free 
rT3 concentrations are high due to a reduction in its renal clearance. 
CKD is associated with a higher prevalence of primary 
hypothyroidism, both overt and subclinical, but not with hyperthyroidism.          
24 
 
In fact, the prevalence of primary hypothyroidism, mainly in the subclinical 
form, increases as GFR decreases 40. A recent study has shown a prevalence 
of subclinical hypothyroidism of 7% in patients with estimated GFR 90 
ml/min per 1.73 m2 that increased to 17.9% in subjects with GFR <60 
ml/min per 1.73 m2 . The prevalence of hypothyroidism is higher in 
women and is associated with an increased frequency of high titers of anti-
thyroid antibodies. 
The prevalence of hyperthyroidism in CKD is similar to that found in 
general population ( 1%), in areas with inadequate intake of iodine. On the 
other hand, uremic patients undergoing dialysis with hyperthyroidism due to 
either Grave’s disease or toxic multinodular goiter can be adequately treated 
with therapeutic doses of I131. Moreover, hyperthyroidism has been 
considered as one of the many causes of anemia resistant to recombinant 
human erythropoietin (rh-EPO) in CKD patients on HD with an adequate 
response to antithyroid treatment. 
The kidney contributes to the iodine clearance primarily 
through glomerular filtration. Serum iodine concentrations are high in CKD 
but are not correlated with the degree of kidney failure. This iodine excess 
has been linked to increased prevalence of goiter and hypothyroidism 
reported in CKD. A high exposure to iodine facilitates the development of 
hypothyroidism in CKD patients. Some authors have reported that a 
restriction of dietary iodine in uremic patients on HD can correct 
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the hypothyroidism avoiding the need for hormone replacement 
with levothyroxine 41. 
EFFECTS OF DIALYSIS ON THYROID FUNCTION: 
Hemodialysis 
Most HD patients are euthyroid. Hypothyroidism is not infrequent in 
these patients. However, a diagnosis of hypothyroidism in HD patients 
should not be made solely on the basis of reduced T4 and T3 levels but 
requires documentation of substantial TSH elevation (TSH>5 mIU/l but <20 
mIU/l may occur in 20% of uremic patients and are more indicative of non-
thyroidal illness than hypothyroidism). HD is associated with alterations in 
the concentration of circulating Thyroid Hormone, usually to a reduction in 
serum total and free T3 concentrations. This reduction is associated with 
systemic acidosis, time on dialysis, and some markers of endothelial damage 
and inflammation. Low Thyroid Hormone may be a protective adaptation for 
nitrogen conservation and therefore inappropriate Thyroid Hormone 
supplementation can result in excessive protein nitrogen wasting in these 
patients. HD influences the cellular transport of Thyroid Hormone. This 
effect could act as a compensatory mechanism to neutralize the thyroid 
dysfunction in order to maintain euthyroid status 42. 
Treatment with ablative dose of I131 has been successfully used in the 
treatment of differentiated thyroid carcinoma in patients on HD 
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Peritoneal dialysis: 
The most common thyroid dysfunction in peritoneal dialysis 
(PD) patients is primary hypothyroidism, especially subclinical 
hypothyroidism (27.5%) 43. This entity might be implicated in cardiac 
dysfunction in PD patients due to the fact that these patients show lower left 
ventricular ejection fractions and fractional shortening at endocardial levels 
compared with those with normal TSH levels. Other common alteration in 
thyroid function tests is low T3 syndrome (16%). The high protein loss 
induced by this type of dialysis could be related to an increased incidence of 
thyroid dysfunction. One of the important issues in PD patients is the 
continuous loss (due to the continuous nature of the method) of substantial 
amounts of proteins in the peritoneal cavity. Nevertheless, TBG 
concentrations remain within normal limits in these patients. When 
hypothyroidism develops, left ventricular function can be compromised but 
this is not specific to PD patients. 
Thyroid function and renal transplantation 
Kidney transplantation is associated with abnormalities in 
thyroid function, mainly a reduction in T3 concentrations. An independent 
relationship between T3 with different markers of endothelial dysfunction 
has been reported. Both thyroid volume and serum concentration of free 
T3 are correlated with the graft function. A positive correlation between 
serum creatinine and thyroid volume has been found. Patients with 
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diminished values of T3 before transplantation are at increased risk of graft 
failure, thus suggesting that T3 quantification might be a potential marker for 
this risk. However, treatment with T3 does not appear to prolong the half-life 
and function of the graft 44. 
MANAGEMENT 
Several studies have been conducted in patients with the T3 syndrome 
in order to correct the thyroid profile by treating with Levothyroxine and 
Triiodothyronine. 
Gregory Brent et al.47 conducted study in non-thyroidal illness patients by 
treating all the patients with serum total T4 less than 5 μg/dl with 1.5 μg/Kg 
of Levothyroxine for 2 weeks. Thyroxine level increased significantly in 
treated patients. Serum T3 levels were also raised. But mortality was 
increased in treatment group on day 5 – 17. 
Carter et al.48 studied effects of Triiodothyronine administration in 
patients with chronic renal failure. Study showed serum T3 level did not 
change over a period of 12 weeks. But the mean serum T4 and TSH levels 
were affected significantly. There was no subjective improvement  in these 
patients. 
Based on this observation, it has been suggested that low serum T3 
level in patients with severe renal failure is metabolically protective and it is 
interpreted as physiological adaptation to reduce basal metabolic rate (BMR) 
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and to conserve energy in an adverse environment. Hence, this condition has 
been renamed as “Thyroid hormone adaptation syndrome” 
 Administration of T4 or T3 causes suppression of TSH and increases 
the catabolism. So, administration of thyroid hormone is not beneficial. 
Study also showed increased morality with the treatment. Therefore, thyroid 
hormone should not be given in CRF unless true hypothyroidism can be 
documented. 
Thyroid function, morbidity, and mortality in kidney disease 
There is a relationship between plasma levels of T3 and 
various markers of inflammation, nutrition, and endothelial activation in 
patients with CKD 45. These patients show an association between low serum 
values of T3 with inflammation markers (elevated levels of high sensitivity 
C-reactive protein, interleukin 6(IL-6) and vascular adhesion molecule-1) 
and nutrition (decrease of albumin and IGF-1), and cardiac function. The 
lower the concentration of T3, the greater the degree of inflammation and 
poorer the nutritional status and cardiac function. Therefore, low T3 is 
associated with a survival disadvantage. The relationship between survival 
and T4 is less defined. 
A reduction in total T3, but not in free T3 concentrations 
was associated with an increased all-cause and cardiovascular mortality in 
euthyroid CKD patients. Total and free T3 behave as survival markers in 
patients with CKD both in HD and in PD. For these reasons, some authors 
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have recommended measuring T3 levels to assess the relationship between 
thyroid dysfunction and risk of mortality in this population. Finally, it has 
been recently reported that low levels of T3 before renal transplantation are 
associated with decreased survival of the graft. 
Several factors, including malnutrition and intercurrent processes, may 
be involved in the reduction of serum T3 in uremic patients. Fasting and 
disease alter iodothyronine deiodination, thus reducing peripheral production 
of T3. The presence of chronic protein malnutrition is associated with a 
reduction of binding protein synthesis and could reduce plasma total 
T3 concentration. TNF-α and interleukin-1 inhibit the expression of type 1 
5'-deiodinase, the enzyme responsible for T4 to T3 conversion in 
peripheral tissues. This would explain how chronic inflammation and 
vascular damage associated to CKD, interfere with the normal process of 
 T3 synthesis from T4 46. 
SUMMARY: 
Kidney and thyroid function and dysfunction are interrelated through 
several mechanisms. From a clinical perspective, in patients with 
kidney disease, it is generally sufficient to use thyroid function tests 
commonly used in the clinic. However, to avoid mistakes in diagnosis, it is 
important to know the effects of hypothyroidism and hyperthyroidism on 
renal function, as well as the changes in thyroid function tests induced by 
chronic kidney disease. Drugs used in the treatment of thyroid and 
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kidney diseases may induce changes in renal and thyroid physiology  
respectively. Treatment of CKD by HD, PD or renal transplantation is also 
accompanied by specific changes in thyroid physiology. In patients with 
differentiated thyroid carcinoma, some modifications in the usual therapies 
may be necessary, especially in the dose of I131, in the presence of a decline 
in renal function. On the other hand, recent investigations have shown 
interesting relationships in neoplastic diseases affecting the thyroid and the 
kidney. A relationship between T3 levels and mortality has been proven in 
uremic patients. The relationship between TSH and survival, well established 
in other population groups, has not been reported in patients with different 
degrees of kidney insufficiency. 
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MATERIALS AND METHODS 
Study group 
Patients admitted to the Medical Ward in TIRUNELVELI MEDICAL 
COLLEGE HOSPITAL with chronic renal failure who are on conservative 
management. 
Study design 
       Single Centre, Cross-sectional study 
Study period 
       Study was conducted between September 2009-  September 2010 for 
a period of 12 months. 
Sample size 
In the study period of 12 months, among patients admitted in Medical 
Ward after applying inclusion and exclusion criteria, 50 patients were 
included in this study. Patients who fulfill the criteria for CRF and who are 
on conservative management were taken for the study. Thyroid profile is 
done in all patients who fulfill the criteria. 
Informed consent was Obtained from all patients 
Inclusion Criteria for Chronic Renal Failure 
1. Symptoms of uremia for 3 months or more. 
2. Elevated blood urea, serum creatinine and decreased creatinine 
clearance. 
 
32 
 
3. Ultra sound evidence of chronic renal failure: 
a) Bilateral contracted kidneys – size less than 8 cm in male 
and female. 
b) Poor corticomedullary differentiation. 
4. Supportive laboratory evidence of CRF like anemia, low 
specific gravity, changes in serum electrolytes, etc., 
5. Radiological evidence of renal osteodystrophy. 
Exclusion criteria 
1. Patients underwent peritoneal dialysis or hemodialysis. 
2. Nephrotic range of proteinuria. 
3. Low serum protein especially albumin. 
4. Other conditions like: 
a. Acute illness 
b. Recent surgery, trauma or burns 
c. Diabetes mellitus 
d. Liver diseases 
e. Drugs altering thyroid profile like amiodarone, steroids, 
dopamine, phenytoin, beta-blocker, estrogen pills and iodine-
containing drugs. 
Detailed clinical history and examination is undertaken with 
preference to thyroid and renal diseases.  
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The following investigations are performed: 
∗ Urine for specific gravity and broad cast 
∗ Renal parameters like blood urea, serum Creatinine and 
creatinine clearance (using Modified diet and renal disease ) 
∗ Serum calcium  
∗ Serum cholesterol for hypothyroidism 
∗ 24 hours urine protein and serum protein to rule out nephrotic 
syndrome and hypoproteinemia respectively 
∗ ECG and chest X ray to look for features for hypothyroidism and renal 
failure like pleural effusion, pericardial effusion 
∗ X ray wrist, forearm and spine for evidence of renal osteodystrophy  
∗ USG abdomen for evidence of chronic renal failure. 
After selecting the patients, fulfilling the above criteria, about 5 ml of 
blood sample is collected in non-heparinised serum bottle and sent for 
thyroid profile. 
Components of thyroid profile in this study 
∗ Serum triiodothyronine(T3)-70-200 ng/dl. 
∗ Serum thyroxine(T4)-4.5-12.5 µg/dl. 
∗ Serum free T3-1.4-4.0 pg/ml. 
∗ Serum free T4-0.80-2.0 ng/dl. 
∗ Serum thyroid stimulating hormone(TSH)-0.3-5.0µI U/ml. 
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OBSERVATIONS AND RESULTS 
 50 patients with chronic kidney disease who were on conservative 
management were studied. Among 50 patients, 13 patients were female and 
37 patients were male. 
 The duration of CRF in this study varied from 3 months to 1 year. The 
creatinine clearance varied from 3ml/min to 64ml/min. 29 patients had 
creatinine clearance of <15ml/min accounting for 58%, 16 patients had 
creatinine clearance  of 15ml – 29ml / min accounting for 32%, 5 patients 
had creatinine clearance of ≥30ml/min accounting for 10%. 
 24hrs urine protein excretion was <1gm/day in all patients in this 
study group. Serum calcium was normal in all patients. 70% of the patients 
had anemia with peripheral smear revealing normocytic normochromic 
anemia in 50% and hypochromic anemia in 20% of the patients. 4 patients in 
this study had pleural effusion, 1 patient showed evidence of osteodystrophy.  
STATISTICAL ANALYSIS 
The prevalence of thyroid dysfunction in chronic kidney disease trial 
was described and analyzed in terms of percentages and averages. The 
analytical data was interpreted by students unpaired and students 
proportion‘t’ test. The relations between the related biochemical variable in 
CKD were analyzed and interpreted by the point biserial correlation 
coefficient (rp1bis). The correlation between the thyroid indices were analyzed 
and interpreted by the Karl Pearson’s coefficient(r). The above analysis and 
interpretation of statistical procedures were performed by the statistical 
package S.P.S.S.(13). The value of P <0.05 was considered as significant. 
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RESULTS 
The clinical trial was described and analyzed according to their age, 
sex and prevalence of thyroid dysfunction. 
 
TABLE 1: SEX WISE AGE DISTRIBUTION OF PATIENTS TAKEN 
FOR STUDY 
Age group 
in years 
Male Female Total 
frequency % frequency % frequency % 
30-39 8 21.6 0 Nil 8 16 
40-49 4 10.8 5 38.4 9 18 
50-59 10 27 6 46.2 16 32 
60-69 15 40.5 2 15.4 17 34 
total 37 100 13 100 50 100 
Median age 55(35-69) 55(40-62) 55(35-69) 
mean±S.D. 53.8±11.8 51.5±7.2 52.7±10.3 
‘t’ 0.486 
Significance d.f.=48 P>0.05 
 
The sex wise age distribution shown in the table 1 reveals that the 
median age of the males and females and total clinical trials was 55 years. 
The mean age of the total subjects was 52.7±10.3 years. The mean age of the 
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male and female patients was 53.8±11.8 and 51.5±7.2 years respectively. 
The difference between the mean   age of the male and female was 
statistically not significant P>0.05. The male participation was 74% and the 
female participation was 26%. 
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TABLE 2 : SEX WISE PREVALANCE OF THYROID 
DYSFUNCTION IN CKD PATIENTS 
Thyroid 
hormones 
Level of 
hormone 
No Males, n=37 Females=13 ‘t’ Significance
frequency % frequency % 
T3 low 27 18 48.6 9 69.2 1.354 P>0.05 
normal 23 19 51.4 4 30.8 
T4 low 11 7 18.9 4 30.8 0.830 P>0.05 
normal 39 30 81.1 9 69.2 
TSH high 2 1 2.7 1 7.7 0.636 P>0.05 
normal 48 36 97.3 12 92.3 
 
The prevalence of thyroid dysfunction among the sexes was shown in 
the above table 2. The prevalence of low T3 syndrome was 54% (27 cases) 
and the low T4 syndrome was 22 % (11 cases). The prevalence of TSH in 
hypothyroidism range was 4 %( 2 cases). Among the males 48.6% of 
patients had low T3 syndrome. And among the females was 62.2%. The 
difference was not statistically significant P>0.05. The prevalence of low T4 
among the males was 18.9 % and among the females was 30.8%. The 
difference among the sexes was not statistically significant i.e. P>0.05. The 
prevalence of TSH in clinical hypothyroidism range among males was 2.7%. 
And among the females was 7.7%. The prevalence between the sexes was 
not statistically significant (P>0.05). 
38 
 
 
 
 
 
 
 
 
51.4
30.8
48.6
69.2
0
10
20
30
40
50
60
70
80
Male Female
Pe
rc
en
ta
ge
 o
f c
as
es
Total T3
Sexwise Distribution of Total T3 Level
normal
low
81.1
69.2
18.9
30.8
0
10
20
30
40
50
60
70
80
90
Male Female
Pe
rc
en
ta
ge
 o
f c
as
es
Free T4
Sexwise Distribution of Free T4 Level
normal
low
39 
 
TABLE 3: AGE WISE THYROID HORMONES AND TSH 
DISTRIBUTION TAKEN FOR STUDY 
Age group Frequency Mean  
Total T3 
Mean 
Free T4 
Mean 
TSH 
30-39 8 75.8±23.8 0.8±0.2 11±25.9 
40-49 9 70.4±33.5 0.9±0.2 3±3.2 
50-59 16 71.4±26.3 1.1±0.2 1.3±1.2 
60-69 17 95.3±33.6 1.1±0.3 1.3±1 
Total 50 80±31.1 1±0.3 3.2±10.5 
 
 The above table 3 reveals that the mean level of thyroid biomarkers 
does not show significant difference in the various age groups. 
TABLE 4: DISTRIBUTION OF TOTAL T3 FREE T4 AND TSH IN 
VARIOUS STAGES OF CKD 
Stages of 
CKD 
Frequency Mean  
Total T3 
Mean  
free T4 
Mean  
TSH 
1-3 5 103.4±30.7 1.25±0.1 1.8±1.9 
4 16 91±36.6 1.1±0.2 1.2±0.8 
5 29 68.8±24 0.9±0.3 4.5±13.7 
 
The above table 4 reveals the mean T3, free T4 and TSH levels in 
various stages of CKD. The mean T3 is decreased significantly with reduced 
creatinine clearance. The free T4 is also significantly decreased in stage 5 
CKD.  
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TABLE 5 : RELATIONSHIP BETWEEN CREATININE 
CLEARANCE WITH TOTAL T3, FREE T4 AND TSH 
Relation with Cr. 
Clearance 
r Significance 
Total T3 0.320 P<0.05 
Free T4 0.381 P<0.01 
TSH -0.133 P>0.05 
 
The above table shows positive correlation between total T3 and 
Creatinine clearance and it is statistically significant. The free T4 and 
creatinine clearance shows positive correlation and it is statistically 
significant. The above table shows negative correlation of TSH with 
creatinine clearance and it is not statistically significant. 
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CORRELATION OF TOTAL T3 WITH CREATININE CLEARANCE  
 
 
 
CORRELATION OF FREE T4 WITH CREATININE CLEARANCE  
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TABLE 6: CORRELATION OF TOTAL T3 WITH CREATININE 
CLEARANCE 
Creatinine 
clearance 
ml/min 
T3 
dysfunction 
Normal Total rp1bis d.f. Significance
No. % No. % No. % 
60-89 0 0 1 4.3 1 2  
 
 
-
0.316
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P<0.05 
30-59 1 3.7 3 13 4 8 
15-29 6 22.2 10 43.5 16 32 
<15 20 74.1 9 39.1 29 58 
total 27 100 23 100 50 100
Mean±S.D 12.2±8.6 20±14.8 15.8±12.3
‘t’ 2.338 
Significance P<0.05 
 
The table 6 explains the relation between the creatinine clearance with 
total T3. The mean creatinine clearance in low T3 syndrome was 12.2±8.6 
ml and  in normal patients was 20±14.8 ml. The difference between the 
patients was statistically significant i.e. P<0.05. The rp1bis  determines the 
direction between the creatinine clearance with low total T3 patients. The 
dysfunction with creatinine clearance was negatively correlated i.e.  rp1bis  = -
0.316. Statistically explain the negative relationship between them 
significantly i.e. P<0.05. 
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TABLE 7 : RELATIONSHIP BETWEEN CREATININE 
CLEARANCE WITH FREE T4 
Creatinine 
clearance 
ml/min 
FREE T4 
dysfunction 
Normal Total rp1bis d.f. Significance
No. % No. % No. % 
60-89 0 0 1 2.6 1 2  
 
 
-0.340 
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P<0.05 
30-59 0 0 4 10.3 4 8 
15-29 1 9.71 15 38.5 16 32 
<15 10 90.4 19 48.6 29 58 
Total 11 100 39 100 50 100
Mean±S.D 7.9±4 18±13 15.8±12.3
‘t’ 2.518 
Significance P<0.05 
 
The table 7 describes the correlation between the creatinine clearance 
with free T4. The mean creatinine clearance with low free T4 dysfunction 
and normal patients was 7.9±4 and 18±3 ml respectively. The difference 
between the mean was statistically significant i.e. P<0.05. The point biserial 
correlation coefficient i.e. rp1bis = -0.340 illustrated the negative correlation. 
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The relationship displayed in the table 8 reveals the mean creatinine 
clearance in TSH dysfunction and normal were 5±1.4 and 16.2±12.4 ml 
respectively. The difference between the mean was not statistically 
significant i.e.P>0.05.  
 
TABLE 9: PREVALANCE OF GOITER IN CHRONIC KIDNEY 
DISEASE PATIENTS 
S.No. Disease No. % 
1 Goiter 2 4 
2 
Goiter with pleural 
effusion 1 2 
3 No evidence 47 94 
 
The above table 9 describes the prevalence of goiter in CKD patients. 
Among the 50 patients 47(94%) patients had no evidence of goiter. With 
remaining 3patients 2(4%) patients had exclusively goiter , 1 (2%)patients  
had goiter with pleural effusion . The total  prevalence of goiter in our study 
is 6%. 
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Table-10 : RELATIONSHIP BETWEEN TOTAL T3 WITH TSH 
EXCLUDING HYPOTHYROIDISM 
S.NO. LOW T3 (ng/dl)  TSH (µIU/ml) 
1 64 2.55 
2 61 3.06 
3 60 0.40 
4 64 0.97 
5 70.4 0.87 
6 62 0.49 
7 48 0.49 
8 69 0.96 
9 54 0.46 
10 53 1.61 
11 70 4.35 
12 59 2.13 
13 64 2.71 
14 55 4.85 
15 50 1.52 
16 50 1.80 
17 64 0.64 
18 50 1.20 
19 50 0.74 
20 57 2.12 
21 63 1.01 
22 60 3.17 
23 70 0.30 
24 68 0.99 
25 32 0.50 
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DISCUSSION 
A large number of hormonal systems are affected by CRF, yet it 
remains unclear to what extent these changes are responsible for 
manifestations of uremic syndrome. Patients with CRF often have signs & 
symptoms suggestive of thyroid dysfunction & hence the diagnosis of 
thyroid disease in these patients has obvious prognostic implications. The 
data reported deals primarily with the biochemical parameters. In uremia the 
mean values of both serum T3 & T4 were significantly low. This is 
comparable to Ramiraz et al.3 and Lim VS et al.17study. In our study, out 
of 50 patients 27 patients (54%) had low T3 syndrome.  The prevalence of 
low T3 in stage 1- 3 is 20 %, for stage 4 is 38%, and stage 5 is 70%. This 
observation is consistent with Sang Heon Song et al.4 in which the 
prevalence of low T3 will be increased according to the increase in stage of 
CKD. In our study there is a positive correlation between Total T3 and 
creatinine clearance and it is statistically significant P<0.05.This shows 
serum T3 levels were associated with severity of CKD even in the normal 
TSH level.  
 There was higher frequency of reduced free T4 values in our study 
(22%) which is consistent with Kaptein  et al.5 and Avasthi et al.6 study but 
it is not statistically significant. In our study there is a positive correlation 
between Free T4 and creatinine clearance and it is statistically significant 
P<0.05. Out of the 50 uremic patients 2 patients show TSH >10 µIU/ml.  
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The high serum TSH level is > 75 µIU/ml. Both these patients had very low 
serum T3 concentration which can be explained by the normal feedback 
regulation of the pituitary thyroid axis. One patient is having both goiter and 
pleural effusion. This observation is consistent with Joseph et al.50 who 
studied 175 patients of CRF who had low T3, T4, fT4 but had high TSH 
levels suggested maintenance of pituitary thyroid axis. 48 patients i.e. 96% 
reported normal level of serum TSH ≤5 µIU/ml. Out of 48 patients 25 
patients had low T3 and 9 patients had low total T3 and free T4. So these 25 
patients had normal level of serum TSH in spite of low serum T3 level. They 
demonstrated abnormality in the hypophyseal mechanism of TSH release in 
uremic patients as the TSH response to TRH was blunted. These results are 
consistent with study of Spector et al.49 and Ramirez et al. reported normal 
level of serum TSH in patients of CRF in spite of low serum T3 levels.  
 In Mehta H.J. Joseph et al.7 study low TT3, FT3 and TT4 values is 
seen in clinically euthyroid CKD patients. However finding of normal T4 
values and TSH would indicate functional euthyroid status. It can be 
presumed that free T4 values would fall if these patients develop 
hypothyroidism and TSH values would rise simultaneously. Thus Free T4 
and TSH levels combined can be used for the diagnosis of hypothyroidism in 
presence of CKD. 
52 
 
 Subjects with TSH > 10 µIU/ml and free T4 below the reference range 
have overt primary hypothyroidism and should be treated with thyroid 
hormone replacement.  
  The prevalence of primary hypothyroidism in CKD ranges from 0-
9.5% as evidenced in previous studies. The prevalence of hypothyroidism in 
our study is 4%. This is consistent with results of Kaptein et al.5 
 Ramirez et al.3 reported high prevalence of goiter in CRF patients 
especially those on chronic dialysis. Incidences were increased in end stage 
renal disease. The possible explanation is due to accumulation of iodides in 
thyroid gland due to decreased renal clearance in CRF patients. Study 
conducted by Hegedus et al.8 showed thyroid gland volume was 
significantly increased in patients with CRF. 
 In our study, 3(6%) patients had evidence of goiter. Out of 3 patients, 
1(2%) had clinical and biochemical features of hypothyroidism. Remaining 2 
patients had low T3 level with normal TSH and T4. 
Dialysis 
As stated previously, Hemodialysis and continuous ambulatory 
peritoneal dialysis have shown to affect the thyroid profile independently of 
CRF. Also drugs like heparin, furosemide used during dialysis will affect the 
thyroid profile. 
Kayima et al.9 and Giordano et al.10 have conducted studies regarding 
effect of dialysis on CRF patients with thyroid dysfunction.                    
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This study showed no significant improvement in thyroid profile after 
repeated hemodialysis. 
But in the patients who have undergone renal transplant surgery,most 
of the thyroid function parameters returned to normal with TSH below 
normal. 
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CONCLUSION 
1. The prevalence of thyroid dysfunction in patients with CKD is 54%. 
2. Number of patients with low T3 and T4 syndrome progressively 
increases with severity of renal failure. 
3. Serum level of total T3 and free T4 is directly proportional to 
creatinine clearance level. 
4. Total T3 and free T4 had correlation with the severity of renal failure. 
5. TSH values will be useful to differentiate hypothyroidism from non-
thyroidal illness due to CKD. 
6. Only 6% of the study population had evidence of goiter. 
7. Alteration in the values of T3 and T4 occurs as a part of body 
adaptation mechanism to conserve energy. 
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PROFORMA 
 
Name:                                                     Age:                                             Sex:                     
IPNo:                                                      Occupation:                    
Address: 
Past H/O: 
          HT: Y/N,   
          DM: Y/N, 
          Recent surgery/Trauma: Y/N , 
          Drugs: Y/N 
          Jaundice: Y/N 
          Other systemic illness: Y/N 
          Menstrual and Obstetric History: 
General Exam: 
          1. Nourishment: 
          2. Pallor: 
          3. Facial puffiness: 
          4. Pedal edema: 
          5. Skin texture: 
          6. Thyroid swelling: 
Pulse: 
BP: 
Respiratory rate: 
Temperature: 
CVS: 
RS : 
Abdomen : 
CNS : 
 
 
 
Investigations: 
1. Urine complete examination: 
2. Blood: 
          Hb: gm/dl 
          TC: 
          DC: P %L %E % 
          RBC: Cells/cumm 
          BT: mnte 
          CT: mnte 
          Peripheral smear 
3. Blood 
          Urea: 
          Creatinine: 
          Na+: 
          K+: 
          Ca2+: 
          Serum Cholesterol 
          Serum protein Total 
                                  Albumin 
                                  Globulin 
4. ECG 
5. X-rays 
          Chest X-ray 
          X-ray wrist, forearm, vertebral spine 
6. USG abdomen 
7. 24 hrs urine protein 
 
 
 
 
 
8. Thyroid profile 
           Serum triiodothyroine 
           Serum thyroxin 
           Serum free T3 and serum free T4 
           Serum thyroid stimulating hormone 
 
 
 
 
 
Renal Parameters Miscellaneous
Blood Urea 
(mg/dl)
Sr. Creatinine 
(mg/dl)
Cr. Clearance 
(ml/min)
Total T3 
(ng/dl)
Total T4 
(µg/dl)
Free T3 
(pg/ml)
Free T4 
(ng/dl)
TSH 
(µIU/ml) NIL 
1 43736 63 M       4 185 9.0 6.41 64 4.43 1.16 0.71 2.55 NIL 
2 43926 66 M       6 92 3.8 17 85 4.84 1.5 0.85 1.42 NIL 
3 43846 35 M       5 85 4.0 18 96 5.66 1.82 0.93 0.55 3
4 43976 35 M       4 117 10.0 6 40 1.6 0.91 0.36 75 NIL 
5 44016 40 F       9 243 13.2 3 61 3.93 1.22 0.79 3.06 NIL 
6 44975 60 M       11 58 2.0 36 125 7.43 2.03 1.31 1.09 NIL 
7 44955 52 M       5 68 4.0 17 60 3.92 1.11 0.69 0.4 NIL 
8 44226 40 F       10 108 4.1 13 64 4.43 1.09 0.8 0.97 NIL 
9 43978 35 M       8 110 2.8 28 95 6.54 1.9 1.08 3.21 NIL 
10 42736 65 M       6 80 3.2 13 107 6.24 1.93 1.57 0.73 NIL 
11 43928 67 M       6 190 6.4 9 70.4 4.64 1.39 0.8 0.87 NIL 
12 41972 67 M       12 55 1.2 64 102 6.36 1.65 1.17 1.12 NIL 
13 44343 60 M       5 153 10.0 6 62 5.32 1.34 1.17 0.49 NIL 
14 44296 55 F       6 75 2.3 23 32 6.62 1.32 0.99 0.5 3
15 44978 56 M       8 216 12.0 5 78 4.79 1.45 0.88 0.57 2
16 45570 51 M       6 112 8.0 8 48 3.8 1.07 0.68 0.49 NIL 
17 45069 50 M       7 117 6.5 10 126 7.5 2.24 1.23 0.5 NIL 
18 44207 37 M       4 84 3.2 23 69 5.78 1.32 0.86 0.96 NIL 
19 44396 46 M       8 142 6.8 9 54 4.82 1.18 0.97 0.46 NIL 
20 44121 36 M       3 192 7.8 8 53 3.6 1.16 0.7 1.61 NIL 
21 45213 69 M       10 113 8.7 6 70 4.59 1.39 1.2 4.35 1
22 47161 55 F       10 120 7.5 6 59 5.5 1.2 1.05 2.13 2
23 45577 56 M       7 245 10.6 5 88 5.06 1.65 0.98 5 NIL 
24 46871 38 M       4 96 7.1 9 110 4.62 2.7 0.92 0.57 NIL 
25 46972 42 M       5 137 4.0 18 64 5.72 1.21 1.1 2.71 NIL 
26 45166 45 F       6 198 7.0 7 55 3.57 1.1 0.73 4.85 NIL 
27 45913 50 M       9 109 4.1 16 100 7.59 2.62 1.42 1.11 NIL 
28 46945 50 M       5 121 4.6 14 50 4.85 1.04 1.24 1.52 NIL 
29 46420 65 M       11 123 4.4 14 50 5.62 1.07 1.23 1.8 NIL 
30 46355 55 M       4 160 5.8 11 100 4.85 2.63 1.24 1.82 3
MASTER CHART
S.NO IP. No. Age Sex Symptoms 
Duration (months)
Thyroid Profile
31 46783 55 F       4 128 7.6 6 64 7.02 1.3 1.38 0.64 NIL 
32 45730 36 M       3 85 1.7 49 80 5.54 1.84 1.12 5.27 NIL 
33 44185 46 M       7 158 10.0 6 100 4.61 2.36 0.85 0.55 NIL 
34 41078 63 M       12 89 4.0 16 110 4.54 2.84 0.9 0.72 NIL 
35 28861 57 M       11 77 3.0 23 50 6.39 1.24 1.16 1.2 NIL 
36 32906 62 F       12 55 2.0 27 110 5.78 1.94 0.86 0.94 NIL 
37 41726 65 M       4 87 3.5 19 170 7.2 2.8 1.4 0.54 NIL 
38 42803 60 F       5 42 2.0 27 130 8.2 2.7 1.5 1.73 NIL 
39 40408 55 F       7 53 2.0 28 50 7.7 1.1 1.4 0.74 NIL 
40 48531 60 M       8 45 2.0 36 142 8.56 2.65 1.41 0.77 2,3
41 48518 60 M       8 204 10.0 6 57 3.04 0.99 0.63 2.12 NIL 
42 48149 65 M       9 140 4.0 16 95 6.8 2.11 1.21 1.32 NIL 
43 45956 45 F       6 93 3.6 15 140 5.5 2.8 1.04 0.55 NIL 
44 46871 38 M       4 96 7.1 9 63 4.08 1.26 0.74 1.01 NIL 
45 49009 48 M       3 161 10.0 6 76 5.56 1.72 0.99 2.91 NIL 
46 31487 55 F       7 106 5.8 8 60 8.34 1.26 1.5 3.17 NIL 
47 38721 55 F       11 69 4.0 12 110 4.72 2.62 0.85 0.62 1
48 48912 65 M       7 175 5.9 10 70 4.59 1.36 0.82 0.3 NIL 
49 49044 55 M       12 29 1.9 39 68 7.16 1.32 1.24 0.99 1,2
50 45854 47 F       4 220 12.0 4 20 1.31 0.84 0.46 10.6 1,2
Cr Cl
1 Goiter
2 Pleural effusion
3 Papilloedema
M Male
F Female
Creatinine Clearance
Key to Master Chart
